このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Kiora Pharmaceuticals 将来の成長

Future 基準チェック /06

Kiora Pharmaceuticalsの収益と利益はそれぞれ年間15.7%と35.4%減少すると予測されていますが、EPS は年間39.5% 減少すると予測されています。

主要情報

-35.4%

収益成長率

-39.5%

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	-15.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 May 2024

今後の成長に関する最新情報

Recent updates

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

May 21

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

業績と収益の成長予測

NasdaqCM:KPRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1	-20	N/A	N/A	2
12/31/2025	2	-14	N/A	N/A	3
12/31/2024	17	4	N/A	N/A	3
3/31/2024	16	2	7	7	N/A
12/31/2023	N/A	-13	-10	-10	N/A
9/30/2023	N/A	-13	-9	-9	N/A
6/30/2023	N/A	-12	-10	-10	N/A
3/31/2023	N/A	-12	-11	-11	N/A
12/31/2022	N/A	-14	-10	-10	N/A
9/30/2022	N/A	-17	-11	-11	N/A
6/30/2022	N/A	-15	-11	-11	N/A
3/31/2022	N/A	-15	-11	-11	N/A
12/31/2021	N/A	-14	-11	-11	N/A
9/30/2021	0	-9	-10	-9	N/A
6/30/2021	0	-8	-9	-9	N/A
3/31/2021	0	-7	-8	-7	N/A
12/31/2020	0	-7	-7	-7	N/A
9/30/2020	N/A	-8	-8	-8	N/A
6/30/2020	N/A	-10	-8	-8	N/A
3/31/2020	N/A	-10	-8	-8	N/A
12/31/2019	3	-7	-8	-8	N/A
9/30/2019	3	-7	-8	-8	N/A
6/30/2019	3	-7	-9	-8	N/A
3/31/2019	3	-8	-9	-9	N/A
12/31/2018	2	-11	-11	-11	N/A
9/30/2018	2	-11	-11	-10	N/A
6/30/2018	1	-12	-10	-10	N/A
3/31/2018	1	-13	-11	-11	N/A
12/31/2017	0	-13	N/A	-6	N/A
9/30/2017	1	-14	N/A	-7	N/A
6/30/2017	1	-13	N/A	-7	N/A
3/31/2017	1	-14	N/A	-7	N/A
12/31/2016	1	-13	N/A	-8	N/A
9/30/2016	1	-12	N/A	-8	N/A
6/30/2016	0	-10	N/A	-6	N/A
3/31/2016	N/A	-8	N/A	-4	N/A
12/31/2015	N/A	-17	N/A	-4	N/A
9/30/2015	N/A	-14	N/A	-3	N/A
6/30/2015	N/A	-13	N/A	-3	N/A
3/31/2015	N/A	-12	N/A	-2	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-3	N/A	-2	N/A
3/31/2014	N/A	-4	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: KPRXの収益は今後 3 年間で減少すると予測されています (年間-35.4% )。

収益対市場: KPRXの収益は今後 3 年間で減少すると予測されています (年間-35.4% )。

高成長収益: KPRXの収益は今後 3 年間で減少すると予測されています。

収益対市場: KPRXの収益は今後 3 年間で減少すると予想されています (年間-15.7% )。

高い収益成長: KPRXの収益は今後 3 年間で減少すると予測されています (年間-15.7% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: KPRXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Kiora Pharmaceuticals 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 69% to US$3.83

Price target increased by 42% to US$17.50

Price target decreased by 56% to US$20.00

Price target increased by 39% to US$65.50

No longer forecast to breakeven

Price target decreased to US$11.83

Recent updates

Investor sentiment improves as stock rises 21%

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

New major risk - Revenue and earnings growth

Price target decreased by 69% to US$3.83

New major risk - Share price stability

Price target increased by 42% to US$17.50

Kiora Pharmaceuticals, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Price target decreased by 56% to US$20.00

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target increased by 39% to US$65.50

Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301

Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

High number of new directors

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

High number of new directors

Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022

Kiora Pharmaceuticals reports 1H results

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. Appoints Susan L. Drexler as Interim Chief Financial Officer

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer

Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022

Kiora Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Price target decreased to US$11.83

EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.

Director Steven Boyd has left the company

Director I. Maher has left the company

EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study

No longer forecast to breakeven

Price target decreased to US$13.08

Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)

New 90-day high: US$7.30

EyeGate Pharmaceuticals, Inc. Announces Board Appointments

New 90-day high: US$6.63

EyeGate Pharmaceuticals announces $8M private placement

Price target raised to US$12.83

EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million.

New 90-day high: US$5.21

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Earnings beat expectations

New 90-day low: US$3.57

Price target lowered to US$11.17

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘